Ozone Therapy in Dermatology

Ozone therapy in dermatology refers to the clinical use of ozone-containing gases, ozonated water, or ozonated oils in selected skin-care and wound-related applications. Interest is shaped by ozone’s oxidative and antimicrobial properties, alongside ongoing questions about treatment standardization, delivery methods, safety, and clinical evidence. Its role remains adjunctive or investigational in many settings rather than a substitute for established dermatological care.

The field is moving from broad claims about oxidative effects toward more controlled evaluation of indication, concentration, exposure, administration route, and treatment frequency. Greater attention is being given to infection control, wound management, inflammatory skin conditions, and post-procedure support, while clinicians increasingly distinguish topical preparations from systemic or insufflation-based approaches. Regulatory scrutiny, informed consent, treatment documentation, and compatibility with established therapies are becoming central to responsible adoption.

Artificial intelligence can support this field by organizing heterogeneous clinical records, identifying safety signals, and helping researchers compare outcomes across protocols. Image analysis may assist with longitudinal assessment of wound closure, erythema, lesion change, and treatment response, provided datasets are clinically validated and representative. AI does not resolve questions about ozone toxicity, optimal dosing, or comparative effectiveness; those issues still require prospective studies, transparent reporting, and clinician oversight.

North America is characterized by strong emphasis on evidence standards, device oversight, and professional liability. Latin America has established interest in complementary and procedural applications, but practice can vary by jurisdiction and institution. Europe places substantial weight on harmonized safety requirements, clinical documentation, and integration with dermatology and wound-care pathways. The Middle East is influenced by private specialty-care investment and regulatory differences between countries. Africa’s opportunities are closely linked to affordability, infection-control capacity, and access to specialist training. Asia-Pacific combines advanced dermatology systems in some markets with diverse traditional, complementary, and private-care settings, making protocol standardization particularly important.

ASEAN countries present varied healthcare infrastructures and regulatory approaches, requiring locally appropriate training and product oversight. BRICS members span substantial differences in research capacity, public-health priorities, and access to dermatology services, so evidence transfer should not be assumed across all settings. The European Union emphasizes coordinated regulation and clinical-quality expectations, although implementation remains national in important areas. G7 systems generally prioritize rigorous evidence, safety monitoring, and integration with established care. GCC markets often combine advanced private healthcare facilities with imported technologies and country-specific approval processes. NATO members do not constitute a single healthcare market, but shared interests in resilience, procurement quality, and clinical preparedness can support collaboration on standards.

Australia and Canada generally emphasize regulated practice, clinical governance, and evidence-based dermatology. Brazil and Mexico have active private and complementary-care environments, making practitioner training and product quality important considerations. China and India combine substantial dermatology demand with diverse hospital, private, and traditional-care systems; local clinical evidence and manufacturing controls are relevant to implementation. Japan and South Korea typically emphasize advanced procedural care, quality assurance, and technology validation. France, Germany, Italy, and Spain operate within the European regulatory context while retaining distinct reimbursement and clinical-practice structures. The United Kingdom places strong weight on evidence appraisal, professional standards, and service governance. The United States requires careful attention to device regulation, scope of practice, clinical documentation, and informed consent. Russia’s adoption environment is shaped by national regulation, institutional capacity, and access to validated equipment.

Leaders should define narrowly scoped clinical indications, use validated equipment and materials, and establish documented protocols for concentration, exposure, ventilation, contraindications, and adverse-event response. Adoption decisions should be based on comparative clinical evidence rather than promotional claims, with independent review of product quality and operator training. Organizations should pair any implementation with prospective outcome tracking, standardized photography, patient-reported measures, and clear escalation pathways. Partnerships with dermatology, wound-care, infection-control, and regulatory specialists can improve governance, while transparent patient communication should explain uncertainty and distinguish adjunctive use from proven first-line treatment.

This executive summary uses a structured qualitative review framework focused on clinical use, technology development, safety, regulation, and healthcare-system context. Interpretation should distinguish evidence by ozone formulation, route of administration, indication, comparator, and study design. Relevant assessment dimensions include clinical outcomes, adverse events, treatment reproducibility, practitioner qualifications, device validation, manufacturing quality, and regulatory status. Regional, group, and country comparisons are presented as contextual analyses rather than measures of commercial performance, and conclusions should be updated as higher-quality clinical and regulatory evidence becomes available.

Ozone therapy in dermatology remains an evolving field whose practical role depends on indication-specific evidence, safe delivery, and appropriate clinical oversight. The most defensible path is selective, adjunctive integration within established dermatological pathways, supported by validated protocols and transparent monitoring. Regional and national differences make consistent training, regulatory alignment, and locally relevant research essential. Artificial intelligence may improve evaluation and surveillance, but it should complement-not replace-clinical judgment and rigorous dermatological research.